Medtronic Archives - Page 48 of 59 - Medical Design Sourcing

How CGM tech has advanced in the 21st century

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control.

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history.

Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose testing wasn’t commercialized until 1908, establishing a foundation for diabetes care.

Elkhart, Ind.–based Ames Company refined the process in 1945 with the introduction of Clinitest reagent tablets, which are still commercially available, albeit from Bayer. The company would introduce the first blood glucose test strip in 1965. The Dextrostix-branded strips were intended for use in doctors’ offices.

In the 1970s, Ames developed a device known as the Ames Reflectance Meter to m…

MedTech 100 roundup: Industry sees largest fall since October

The medtech industry’s hot start to 2021 has finally come to a full halt after stocks fell harder than they had in more than four months.

MassDevice‘s MedTech 100 index ended the week (March 5) at 103.3 points, marking a -3.1% dip from the 106.65-point mark set one week before (Feb. 26). In less than a month, the fall has been more than seven points from the end-of-week tally of 110.63 points on Feb. 12.

Medtech’s lowest point of the week was on Thursday, March 4, when it fell to 102.85. The overall drop of about five points from the 107.88-point mark set on Monday, March 1, is the largest dip since the index slid from 97.2 to 91.01 between Oct. 23, 2020, and Oct. 30, 2020.

The all-time best for the index was 110.96, set just three days after that. The index had never reached even the 100-point mark before November 2020.

Still, the industry is in much better condition than it was around this time last year. Medtech’s latest mark means …

DTW Podcast: Can AI, advanced imaging and robotics “democratize” surgery?

A new generation of digital surgery systems will level the playing field for surgeons giving them artificial intelligence, robotic tools and other assistive technologies.

In three interviews in this week’s DeviceTalks Weekly Podcast, leaders form Asensus, ActivSurgical and Memic explain how their systems will improve surgeon performance, reduce errors, and deliver the “democratization” of surgical robotics.

Guests this week include

Anthony Fernando, CEO of Asensus Surgical (formerly Transenterix), outlines the company’s bid to push its Sehance system as a solution for laparoscopic procedures. Fernando, who took over as CEO in 2019, explains why the company’s stock crashed in 2019 and details the changes that he says has started the company’s turnaround. Senhance offers more responsive surgical tools along with data that will help with surgical training and scheduling.

Todd Usen, CEO of ActivSurgical, left a job he loved at Olympus to lead a compan…

Medtronic launches DCB for dialysis patients in Japan

Medtronic (NYSE:MDT) this week said it launched its first drug-coated balloon in Japan for patients undergoing hemodialysis.

The company launched its In.Pact AV drug-coated balloon, which is indicated for the treatment of obstructive lesions up to 100 mm in length in the native arteriovenous dialysis fistulae in patients with end-stage renal disease and undergoing hemodialysis. It is the first drug-coated balloon to be approved in Japan for that vessel bed, according to Medtronic.

Get the full story on our sister site, Medical Tubing + Extrusion.

Medtronic launches IDE trial for AFib tech

Medtronic (NYSE:MDT) announced today that it administered the first procedures of its Pulsed AF AFib treatment pivotal trial.

The investigational device exemption (IDE) trial is evaluating the PulseSelect pulsed field ablation (PFA) system that uses pulsed electric fields to treat AFib. The FDA granted the company approval to move forward with the IDE trial to evaluate the safety and effectiveness of the PulseSelect in January 2020.

Fridley, Minn.-based Medtronic’s platform uses the electric fields to ablate or create lesions and scar tissue, interrupting irregular electrical pathways in the heart and the triggers of AFib. Unlike traditional methods, PFA treatment is non-thermal and selectively targets cardiomyocytes (heart muscle cells) while avoiding other types of tissue.

According to a news release, Dr. Nitesh Sood performed the first procedure in the trial at Southcoast Health in Fall River, Mass. Dr. Arnoldas Giedrimas performed the second pr…

Medtronic hiring Walmart exec to run its supply chain

Image from Geoff Martha on LinkedIn

Medtronic CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain.

In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of Global Operations and Supply Chain.”

Get the full story at our sister site, Medical Design & Outsourcing.

Medtronic hiring Walmart exec to run its supply chain

Image from Geoff Martha on LinkedIn

Medtronic (NYSE:MDT) CEO Geoff Martha announced that the company is appointing Greg Smith as EVP of global operations and supply chain.

In a LinkedIn post today, Martha wrote: “I’m pleased to share that Greg Smith, Executive Vice President of U.S. Supply Chain for Walmart, is joining Medtronic on April 5 as Executive Vice President of Global Operations and Supply Chain.”

The Medtronic CEO added that the Walmart executive currently heads one of the world’s “largest and most complex supply chains” for the massive retail company.

Smith developed and implemented a strategy to transform Walmart’s supply chain in an effort to drive sales and reduce costs while creating an engaging work environment. He also built Walmart’s sales and operations planning and quality organizations to improve forecast accuracy in pursuit of zer…

Medtronic wins city council approval for 42-acre campus in Colorado

The Lafayette, Colo., City Council voted this week to approve Medtronic’s (NYSE:MDT) plans for a 42-acre campus located in the city.

Medtronic confirmed the approval in a statement to MassDevice:

“On March 2, the Lafayette City Council provided final approval to Medtronic’s proposed Lafayette, Colorado, campus plans,” the company said. “This vote clears the way for Medtronic to proceed with the phased construction of a world-class innovation and research center that will bring together 2,000+ employees from Boulder and Louisville facilities onto one campus.

“We plan to build two five-story connected buildings on about 40 acres. Medtronic expects to close on the land acquisition this spring and begin construction six to eight weeks after the close. As we’re taking a phased approach, the entire construction process will take about two years to complete. We believe employees w…

5 reasons Medtronic’s CEO is optimistic about the future

Geoff Martha, CEO of Medtronic

Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming.

In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more.

Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are five reasons why he’s optimistic about the company’s future.

Next>>

DeviceTalks by MassDevice · Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently

Medtronic is changing a lot: Here’s what you need to know

CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere.

In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s strong third quarter-results and spoke of the programs giving him the most optimism. (Here are five things that make Martha especially optimistic about Medtronic’s future.)

He also updated listeners on the reorganization plan that created 20 semi-autonomous operating units.

“We took out over two layers of the company, which helps with our agility,” Martha said. “The dust is settling. But this operational model is much broader than structural things. This is like going from mainframe to PC, but we still have to rewrite the software.&…

5 reasons Medtronic’s CEO is optimistic about the future

Medtronic CEO Geoff Martha

Nearly a year after Geoff Martha took over the corner office at Medtronic, the world’s largest medical device company is transforming.

In a recent interview with our DeviceTalks Weekly podcast, Martha detailed Medtronic‘s major reorganization, its shift in corporate culture and more.

Martha was also highly pleased about Medtronic’s recent Q3 earnings results. Here are five reasons why he’s optimistic about the company’s future.

Next>>

DeviceTalks by MassDevice · Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently

Medtronic is changing a lot: Here’s what you need to know

CEO Geoff Martha says Medtronic‘s ongoing corporate restructuring will position the company to compete better with medical device rivals, freeing the front-line forces from earlier entanglements. But the change will also create new opportunities for Medtronic employees at the company and elsewhere.

In a far-ranging interview with the DeviceTalks Weekly podcast, Martha reviewed the company’s strong third quarter-results and spoke of the programs giving him the most optimism. (Here are five things that make Martha especially optimistic about Medtronic’s future.)

He also updated listeners on the reorganization plan that created 20 semi-autonomous operating units.

“We took out over two layers of the company, which helps with our agility,” Martha said. “The dust is settling. But this operational model is much broader than structural things. This is like going from mainframe to PC, but we still have to rewrite the software.&…